1
|
Sasikumar SC, Goswami U, Raichur AM. 3D Bioprinting with Visible Light Cross-Linkable Mucin-Hyaluronic Acid Composite Bioink for Lung Tissue Engineering. ACS APPLIED BIO MATERIALS 2024; 7:5411-5422. [PMID: 38996006 DOI: 10.1021/acsabm.4c00579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/14/2024]
Abstract
3D printing can revolutionize personalized medicine by allowing cost-effective, customized tissue-engineering constructs. However, the limited availability and diversity of biopolymeric hydrogels restrict the variety and applications of bioinks. In this study, we introduce a composite bioink for 3D bioprinting, combining a photo-cross-linkable derivative of Mucin (Mu) called Methacrylated Mucin (MuMA) and Hyaluronic acid (HA). The less explored Mucin is responsible for the hydrogel nature of mucus and holds the potential to be used as a bioink material because of its plethora of features. HA, a crucial extracellular matrix component, is mucoadhesive and enhances ink viscosity and printability. Photo-cross-linking with 405 nm light stabilizes the printed scaffolds without damaging cells. Rheological tests reveal shear-thinning behavior, aiding cell protection during printing and improved MuMA bioink viscosity by adding HA. The printed structures exhibited porous behavior conducive to nutrient transport and cell migration. After 4 weeks in phosphate-buffered saline, the scaffolds retain 70% of their mass, highlighting stability. Biocompatibility tests with lung epithelial cells (L-132) confirm cell attachment and growth, suggesting suitability for lung tissue engineering. It is envisioned that the versatility of bioink could lead to significant advancements in lung tissue engineering and various other biomedical applications.
Collapse
Affiliation(s)
- Sruthi C Sasikumar
- Department of Materials Engineering, Indian Institute of Science Bangalore, Karnataka 560012, India
| | - Upashi Goswami
- Department of Materials Engineering, Indian Institute of Science Bangalore, Karnataka 560012, India
| | - Ashok M Raichur
- Department of Materials Engineering, Indian Institute of Science Bangalore, Karnataka 560012, India
- Institute for Nanoscience and Water Sustainability, University of South Africa, the Science Campus, Florida Park, 1710 Roodepoort, Johannesburg 1735, South Africa
| |
Collapse
|
2
|
Rodrigo MJ, Cardiel MJ, Fraile JM, Mayoral JA, Pablo LE, Garcia-Martin E. Laponite for biomedical applications: An ophthalmological perspective. Mater Today Bio 2024; 24:100935. [PMID: 38239894 PMCID: PMC10794930 DOI: 10.1016/j.mtbio.2023.100935] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 12/20/2023] [Accepted: 12/27/2023] [Indexed: 01/22/2024] Open
Abstract
Clay minerals have been applied in biomedicine for thousands of years. Laponite is a nanostructured synthetic clay with the capacity to retain and progressively release drugs. In recent years there has been a resurgence of interest in Laponite application in various biomedical areas. This is the first paper to review the potential biomedical applications of Laponite in ophthalmology. The introduction briefly covers the physical, chemical, rheological, and biocompatibility features of different routes of administration. After that, emphasis is placed on 1) drug delivery for antibiotics, anti-inflammatories, growth factors, other proteins, and cancer treatment; 2) bleeding prevention or treatment; and 3) tissue engineering through regenerative medicine using scaffolds in intraocular and extraocular tissue. Although most scientific research is not performed on the eye, both the findings and the new treatments resulting from that research are potentially applicable in ophthalmology since many of the drugs used are the same, the tissue evaluated in vitro or in vivo is also present in the eye, and the pathologies treated also occur in the eye. Finally, future prospects for this emerging field are discussed.
Collapse
Affiliation(s)
- Maria J. Rodrigo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
| | - Maria J. Cardiel
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
- Department of Pathology, Lozano Blesa University Hospital, Zaragoza, Spain
| | - Jose M. Fraile
- Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza–CSIC, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain
| | - Jose A. Mayoral
- Institute for Chemical Synthesis and Homogeneous Catalysis (ISQCH), Faculty of Sciences, University of Zaragoza–CSIC, C/Pedro Cerbuna 12, 50009 Zaragoza, Spain
| | - Luis E. Pablo
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
- Biotech Vision SLP (spin-off Company), University of Zaragoza, Spain
| | - Elena Garcia-Martin
- Department of Ophthalmology, Miguel Servet University Hospital, Zaragoza, Spain
- Aragon Institute for Health Research (IIS Aragon), GIMSO Research Group, University of Zaragoza (Spain), Avda. San Juan Bosco 13, E-50009 Zaragoza, Spain
| |
Collapse
|